X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
Details:
Theramex will commercialise and distribute Eladynos (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures on an exclusive basis in the European Economic Area, UK , Australia and Brazil.
Lead Product(s): Abaloparatide Acetate
Therapeutic Area: Musculoskeletal Product Name: Eladynos
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Theramex
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 20, 2023
Details:
Radius’ lead product, TYMLOS® (abaloparatide) was launched in the U.S. in 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Lead Product(s): Abaloparatide Acetate
Therapeutic Area: Musculoskeletal Product Name: Tymlos
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Gurnet Point Capital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 15, 2022
Details:
The acquisition of Radius by Gurnet Point and Patient Square provides our shareholders with attractive, immediate value at a compelling premium, in addition to the potential future upside of TYMLOS (abaloparatide) through the CVR.
Lead Product(s): Abaloparatide Acetate
Therapeutic Area: Musculoskeletal Product Name: Tymlos
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Gurnet Point Capital
Deal Size: $890.0 million Upfront Cash: $547.0 million
Deal Type: Acquisition August 15, 2022
Details:
The acquisition of Radius by Gurnet Point and Patient Square provides our shareholders with attractive, immediate value at a compelling premium, in addition to the potential future upside of TYMLOS (abaloparatide) through the CVR.
Lead Product(s): Abaloparatide Acetate
Therapeutic Area: Musculoskeletal Product Name: Tymlos
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Gurnet Point Capital
Deal Size: $890.0 million Upfront Cash: $547.0 million
Deal Type: Acquisition June 23, 2022
Details:
The data for spine BMD vs. baseline showed abalo-TDS had a 7.1% increase vs. TYMLOS (abaloparatide) +10.9%, both considered clinically meaningful. Despite missing the non-inferiority margin, the transdermal system demonstrated a bone building benefit to patients.
Lead Product(s): Abaloparatide Acetate
Therapeutic Area: Musculoskeletal Product Name: Tymlos
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
Company announced phase 3 topline results from the wearABLe study did not meet its primary endpoint evaluating the NI of BA058 (abaloparatide) in postmenopausal women with osteoporosis.
Lead Product(s): Abaloparatide Acetate
Therapeutic Area: Musculoskeletal Product Name: BA058
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2021
Details:
Endo obtained the rights to abaloparatide-subcutaneous injection and abaloparatide-transdermal patch, a novel formulation and route of administration currently undergoing clinical development. Endo, will be responsible for all commercial activities related to abaloparatide.
Lead Product(s): Abaloparatide Acetate
Therapeutic Area: Musculoskeletal Product Name: BA058
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Endo International
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 05, 2021
Details:
The study was designed to look at the effects on bone mineral density of abaloparatide delivered via a novel transdermal device (“abaloparatide-patch”) compared with the current subcutaneous formulation, marketed as TYMLOS®.
Lead Product(s): Abaloparatide Acetate
Therapeutic Area: Musculoskeletal Product Name: BA058
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
